Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catalent and UMN Pharma Announce Collaboration

Published: Thursday, December 20, 2012
Last Updated: Thursday, December 20, 2012
Bookmark and Share
UMN Pharma will produce a number of biosimilars using Catalent’s GPEx cell lines.

Catalent Pharma Solutions and UMN Pharma Inc. have announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent’s proprietary GPEx® technology.

The development and manufacturing programs will benefit from the GPEx technology producing very stable and high yielding cell lines.

Under the agreement, UMN Pharma and its subsidiary UNIGEN, which is a contract manufacturer, will produce a number of biosimilars using Catalent’s GPEx cell lines.

UMN Pharma, separately, will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales.

UMN Pharma plans to begin multiple biosimilar projects with their alliance companies for the Asian market on an ongoing basis.

“There are great synergies between UMN Pharma and Catalent in terms of technologies, business structure, speed and culture,” commented Masahiro Michishita, Executive Chairman of UMN Pharma.

Michishita continued, “Harnessing Catalent’s broad biologics development and cell construction expertise gives UMN Pharma a unique platform to grow our biosimilars business globally.”

Barry Littlejohns, Catalent’s Business Unit President, added, “This agreement will allow Catalent to continue to grow its biologics development and manufacturing interests of multiple biosimilars and NBEs, particularly in the Asian market. UMN Pharma’s ambitious expansion plans reflect Catalent’s strategy for growth in what we consider to be a key market.”

Hans-Joachim Rohe, President of Catalent Japan added: “We are very excited to offer a continuously expanding range of Catalent services to our customers in Japan. With the growing demand for Catalent’s GPEx technology we enforce our position as leading supplier of drug delivery solutions and expert services.”

Founded in 2004, UMN Pharma now has three manufacturing facilities in Japan focused on the development of influenza vaccines based on insect cells.

Supported by the Japanese government, UMN Pharma currently has three 600L bioreactors for influenza vaccine production.

In response to the emerging demand for influenza vaccines, also for new biological entities (NBEs) and biosimilars, it has commissioned two additional 21,000L units in Gifu, to be operational by 2013. UMN Pharma will then add another two 21,000L facility by 2016.

Catalent’s biologics group has expressed over 360 cell lines for clients, with dozens of on-going clinical trails throughout the world and two products utilizing the GPEx technology currently on the market.

A new facility with 500L and 1000L single use bioreactors for cGMP manufacturing will be opening in Madison, Wisconsin, USA in spring 2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent & Sanofi to Collaborate
Collaboration on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies.
Thursday, January 22, 2015
Catalent and SELLAS Sign Exclusive Agreement
Agreement for therapeutic reprofiling of zolpidem.
Friday, December 12, 2014
Catalent and Valerion Therapeutics Collaborate
Collaboration to bring new treatments for orphan genetic disorders to market.
Thursday, December 04, 2014
Catalent Acquires Micron Technologies
Company adds global particle size technology leader to Industry’s broadest bioavailability and delivery technology offerings.
Friday, November 21, 2014
Catalent Expands Highly Potent and Cytotoxic Clinical Packaging Capabilities
Completion is expected in January 2015.
Friday, November 07, 2014
Catalent Expands its Technology Offerings in Biologics
Company acquires Redwood Bioscience and the SMARTag™ technology platform.
Friday, October 10, 2014
Catalent and Cingulate Therapeutics Sign Exclusive Agreement
Licensing agreement for development of new ADHD treatments.
Friday, September 26, 2014
Catalent And Minomic Collaborate
Collaboration aims to bring new prostate cancer treatment to market.
Friday, September 19, 2014
Catalent Increases Stake in Redwood Bioscience
The increase follows compelling data generated by the SMARTag™ ADC platform.
Tuesday, March 25, 2014
Catalent Announces Agreement with CiRA, Kyoto University
Agreement for one of the first regenerative therapies to employ iPS cells in humans.
Friday, March 14, 2014
Catalent Acquires Relthy in Brazil
Continues major growth drive into emerging markets.
Thursday, October 17, 2013
Catalent Announces Expansion of Optimelt™ HME Capabilities
Expansion of OptiMelt technology to improve bioavailability.
Thursday, October 03, 2013
Catalent and Supernus Partner for Supply of Trokendi XR™
A novel, oral, once-daily formulation of topiramate for the treatment of epilepsy.
Monday, September 23, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
How Cholesterol Leads to Clogged Arteries
A new study shows that when immune cells called neutrophils are exposed to cholesterol crystals, they release large extracellular web-like structures that trigger the production of inflammatory molecules linked to artherosclerosis.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Researchers Discover New Type of Mycovirus
Virus infects the fungus Aspergillus fumigatus, which can cause the human disease aspergillosis.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!